Sequent Medical has closed a USD15.6m series B venture capital financing led by Domain Associates.
Existing investors Versant Ventures and US Venture Partners also participated in the financing.
Nimesh Shah (pictured), principal of Domain, will join Sequent’s board of directors.
"We are privileged to have such a high calibre group of investors, and would like to welcome both Domain Associates as an investor in Sequent and Nimesh Shah as a board member," says Tom Wilder, who joined Sequent Medical in February 2010 as president and chief executive officer. "We will utilise these funds to continue our development programs, including the introduction of our initial WEB product line."
The WEB aneurysm embolization system provides a new treatment alternative for cerebral aneurysms, especially those prone to a high rate of recurrence and treatment.
Sequent Medical was founded by Bob Rosenbluth and Brian Cox, with Versant Ventures and US Venture Partners as founding investors. It is dedicated to the development of devices to advance the endovascular treatment of neurovascular disease conditions.
